Progyny Stock Intrinsic Value – Director of Progyny Trades Company Stock Amidst Growth
December 21, 2023
☀️Trending News
The Director of Progyny ($NASDAQ:PGNY) recently traded the company’s stock amidst continued growth in their services. Progyny is a fertility benefits company that works with employers to provide resources and support to their employees undergoing fertility treatments. They offer a comprehensive range of solutions that cover the full spectrum of fertility needs, from fertility preservation to egg freezing to IVF treatments. Through their partnerships with employers, they are able to make fertility treatments more accessible and affordable for employees. The Director of Progyny’s recent stock trade shows a clear sign of confidence in the company’s future.
With more and more employers offering fertility benefits, Progyny looks poised to continue its rapid growth in the coming years. The company is also working to expand their services to cover additional aspects of infertility care, from mental health support to surrogacy services. This dedication to providing comprehensive fertility solutions makes Progyny a leader in the industry.
Market Price
On Friday, PROGYNY, a medical and reproductive benefits company, saw one of its directors, John S. Jakobson, execute a trade in the company’s stock. This comes after PROGYNY’s stock opened on Friday at $36.1 and closed the day down by 3.8% from its prior closing price of 35.9. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Progyny. More…
| Total Revenues | Net Income | Net Margin |
| 1.03k | 51.98 | 5.0% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Progyny. More…
| Operations | Investing | Financing |
| 202.67 | -108.28 | -8.83 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Progyny. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 726.51 | 211.12 | 5.38 |
Key Ratios Snapshot
Some of the financial key ratios for Progyny are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 49.4% | 82.2% | 5.0% |
| FCF Margin | ROE | ROA |
| 19.3% | 6.6% | 4.4% |
Analysis – Progyny Stock Intrinsic Value
At GoodWhale, we have conducted a thorough analysis of the fundamentals of PROGYNY. Our proprietary Valuation Line has determined a fair value of $69.6 for a PROGYNY share. This means that the current stock price of $34.5 represents an undervaluation of 50.5%. This presents a great potential for investors to benefit from a rebound in the stock price, as it is trading far below its true worth. We believe that PROGYNY is an excellent buy at its current price and our analysis is here to back it up. More…
Peers
Its competitors are Owlet Inc, ATI Physical Therapy Inc, NantHealth Inc.
– Owlet Inc ($NYSE:OWLT)
Owlet Inc is a privately held company that provides smart baby monitoring products and services. The company was founded in 2013 and is headquartered in Lehi, Utah. Owlet’s product line includes the Owlet Smart Sock, a wearable sensor that monitors a baby’s heart rate and oxygen levels; the Owlet Cam, a Wi-Fi connected camera that streams live video and audio to a smartphone; and the Owlet App, which allows parents to track their baby’s health data. Owlet has raised over $50 million in venture capital funding, and its products are available for purchase online and in select retail stores.
– ATI Physical Therapy Inc ($NYSE:ATIP)
ATI Physical Therapy Inc is a provider of physical therapy and rehabilitation services in the United States. The company operates through a network of over 300 physical therapy clinics in 27 states. ATI Physical Therapy Inc offers a variety of services, including physical therapy, occupational therapy, and speech-language pathology. The company also provides a range of rehabilitation services, such as sports medicine, workers’ compensation, and concussion management.
– NantHealth Inc ($NASDAQ:NH)
NantHealth Inc is a healthcare technology company that provides solutions to improve clinical outcomes and patient experience. The company has a market cap of $37.84 million and a return on equity of 14.38%. NantHealth’s solutions are used by healthcare providers to manage and coordinate care for patients. The company’s products and services include electronic health records, clinical decision support, and patient engagement.
Summary
Investors should closely monitor Progyny‘s performance, as the company provides fertility and family-building benefits to employers and their employees. Progyny offers an array of programs and services, such as egg freezing, fertility preservation, in vitro fertilization, and more. Despite the initial stock performance, some investors may still be interested in Progyny’s services due to their innovative approach to reproductive health care and the strong growth potential of the industry as a whole. Those looking to invest should assess their risk tolerance and research the company in order to make the most informed decisions.
